Primary liver cancer, lung cancer
Conditions
Interventions
experimental group:Intravenous infusion of autologous NK cells
Sponsors
The First People's Hospital of Hefei
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years; 2. Gender is not limited; 3. Diagnosed with hepatocellular carcinoma or lung cancer; 4. Patients who have received tumor interventional therapy in the past or received iodine 125 seed implantation for lung cancer at least 6 months ago, and have achieved complete remission by pathological/radiological examination; 5. The vital organs function normally; 6. The remaining life should be at least 3 months; 7. The patients or their guardians are willing to sign the informed consent; 8. Hepatocellular carcinoma patients: Child-Pugh score 60.
Exclusion criteria
Exclusion criteria: 1. The preparation of autologous NK cell preparations failed; 2. Accept other treatments other than tumor intervention; 3. ECOG score > 2; 4. Serum bilirubin>3mg/dl; 5. GFR<40ml/min/1.73MW; 6. Heart left ventricular ejection fraction <40%; 7. Severe asthma; 8. Uncontrolled infection; 9. HIV, HTLV-1, syphilis positive, or other infectious diseases; 10. Currently receiving or may need systemic immunosuppressive therapy; 11. Have taken anticancer drugs before clinical trials; 12. Pregnant patients or patients who are planning to become pregnant or breastfeeding; 13. Have a history of severe allergies; 14. Suffering from serious mental illness; 15. Participating in other clinical trials; 16. The researchers believe that other reasons are not suitable for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of treatment-related adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse-free survival; | — |
Countries
China
Contacts
Public ContactHe Kewu
The First People's Hospital of Hefei
Outcome results
None listed